ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CHF5993 100/6/12.5 μg pMDI HFA-152a

Also written as “CHF5993 200/6/12.5 μg pMDI HFA-152a”.

Its studies are mostly in Asthma, led by Chiesi Farmaceutici.

Furthest: phase 3, since Nov 13, 20232 company-led studies, 1 open or runningNext primary completion: Jun 26, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici21 open or runningphase 3since Nov 13, 2023Nov 13, 2023Jun 26, 2030phase 3 · NCT07858123

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2023First study: phase 3 study in AsthmaFirst studyNCT06264674 · 827 enrolled · Bulgaria, Czechia, Georgia and more
  2. Sep 18, 2026Phase 3 study in AsthmaNCT07858123 · 700 planned · Germany, Italy, Spain

Ahead

  1. Jun 26, 2030Primary completion: phase 3 study in AsthmaNCT07858123

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07858123Asthma · Germany, Italy, Spain3Not yet recruitingJun 26, 2030700
NCT06264674Asthma · Bulgaria, Czechia, Georgia and more3CompletedFeb 18, 2025827

How it is read

Names in the registry

  • “CHF5993 100/6/12.5 μg pMDI HFA-152a”, 1 entry
  • “CHF5993 200/6/12.5 μg pMDI HFA-152a”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.